Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Sanofi

Sanofi Scores A Big Beat As Dupixent Snags The Spotlight, Again

Sanofi stock rose Thursday on strong revenue growth for the company's allergic conditions treatment, Dupixent.

Investors Business Daily

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach for a full day of networking and education.

Benzinga

Big Pharma's Sanofi Enters Licencing Agreement With Private Psychedelics Company Terran

Terran Biosciences is slowly but surely finding its place in the psychedelics industry.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

How To Attend Sanofi Q1 2022 Earnings Conference Call

Sanofi (NASDAQ:SNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results.

Benzinga

Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine

Results from the Phase 1/2 dose-finding study evaluating Sanofi SA's (NASDAQ:SNY) rilzabrutinib in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrate that rilzabrutinib treatment led to a rapid and durable increase in platelet count and supports an acceptable safety profile. Sanofi is investigating…

Benzinga

Why Black and Hispanic seniors are left with a less powerful flu vaccine

At Whitman-Walker Health, Dr. David Fessler and his staff administer high-dose influenza vaccine to all HIV-positive and senior patients. Although the vaccine is roughly three times as expensive as standard flu vaccine, it seems to do a better job at protecting those with weakened immune systems — a major focus…

Tribune News Service

Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May

Sanofi SA (NASDAQ: SNY) plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Did Truist Lower IGM Biosciences' Price Target?

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.…

Benzinga

IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi

Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against

Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

20 Stocks Moving in Tuesday's Pre-Market Session

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY).

Benzinga

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

The FDA has cleared Adagene Inc's (NASDAQ:ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab). The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid tumors. The ADG126-P001 trial is expected to dose the first patients soon. The trial is…

Benzinga

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing…

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Sanofi Shares Are Trading Lower Today

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer,

Benzinga

DRIO: Future Brightens with $40M Raise & Sanofi Deal

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

Benzinga

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

Sanofi SA (NASDAQ:SNY) has signed a collaboration with Adagene Inc (NASDAQ:ADAG) to advance two preclinical immuno-oncology candidates and an option to develop two more. Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones. Under the terms of the agreement, Adagene will be responsible for early-stage research activities to develop…

Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Unstoppable Healthcare Stocks to Buy and Hold in 2022

The healthcare industry has ridden a promising wave of innovation and investments over the past few years. Also, with continuing acceleration in the digital transformation of healthcare and breakthrough developments, with healthcare expenditure expected to grow in the coming years, the industry’s prospects look bright. Therefore, we think healthcare stocks…

Radio France Internationale

France's Sanofi to seek Covid vaccine approval after months of delays

French pharmaceuticals giant Sanofi has said that its Covid-19 vaccine, developed with Britain's GlaxoSmithKline, had delivered positive results after nearly a year of setbacks that left it lagging far behind its rivals.

Evening Standard

New Covid vaccine 100% effective against severe disease, data suggests

A Covid-19 vaccine that showed it is 100 per cent effective in preventing severe disease and hospitalisation in its trial data is seeking regulatory approval.

Benzinga

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are

The Guardian - UK

Sanofi and GSK seek approval for Covid-19 vaccine

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

The Independent UK

New Covid vaccine 100% effective against severe disease, manufacturers say

French pharmaceutical Sanofi and its British partner GlaxoSmithKline hope their vaccine will also be used as a booster

AFP

France's Sanofi to seek Covid vaccine approval after delays

Paris (AFP) - French pharmaceuticals giant Sanofi said Wednesday that its Covid-19 vaccine, developed with Britain's GSK, had delivered positive results after nearly a year of delays left it lagging far behind its rivals.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.